Table 3.
Studies of inhaled aztreonam in CF patients with P. aeruginosa present in sputum (or Burkholderia spp.).
| Study | Preparation | Dose/Frequency | Duration | Patient Population | Key Outcomes after Treatment |
|---|---|---|---|---|---|
| McCoy 2008 [47] | AZLI | 75 mg/BID or TID | 28 days with 56 days of follow-up | n = 211, receiving inhaled tobramycin | Decreased exacerbation rates, improved lung function and respiratory symptoms |
| Retsch-Bogart 2009 [48] | AZLI | 75 mg/TID | 28 days | n = 164 | Improved lung function and quality of life scores, and decreased number of hospital days |
| Oermann 2010 [49] | AZLI | 75 mg/BID or TID | 28 days on, 28 days off (up to 9 cycles) | n = 195 | TID-treated patients demonstrated greater improvements in lung function and respiratory symptoms |
| Assael 2013 [51] | AZLI or TSI | 75 mg/TID (AZLI) or 300 mg/BID (TSI) | 28 days on, 28 days off (up to 9 cycles) | n = 273 | AZLI-treated patients experienced improved lung function compared to TSI |
| Tullis 2014 [52] | AZLI | 75 mg/TID | 24 weeks | n = 100, Burkholderia spp. present in the sputum | No improvement in lung function |
| Flume (2016) [35] | AZLI + TSI | 75 mg/TID + 300 mg/BID | Alternating 28 days of tobramycin, 28 days of aztreonam for 28 weeks | n = 90 | Trend towards a reduction in exacerbations and hospitalizations |
AZLI, aztreonam solution for inhalation; BID, twice a day; TID, three times a day; TSI, tobramycin solution for inhalation.